Archive · 30 Sep 2025
Indian Pharma Expands in Europe Amidst US Protectionism
Indian pharmaceutical companies are buying up businesses in Europe.
One of these companies, Lupin, is buying an eye care medicine company called VISUfarma for a large sum.
Other companies like Zydus are doing the same.
This move is partly because of increasing trade barriers in the United States.
These acquisitions are allowing Indian companies to grow their business in Europe.
Lupin acquired VISUfarma BV, a Netherlands-based company.
The acquisition cost is €190 million.
The deal aims to strengthen Lupin's European presence.
Indian pharma companies are expanding in Europe.
This expansion is happening amid US protectionist measures.
- Who
- Lupin, VISUfarma BV, Zydus Wellness, Zydus Lifesciences, Dr. Reddy’s Labs, Cipla
- What
- Lupin acquired VISUfarma; Zydus Wellness and Zydus Lifesciences also made acquisitions.
- When
- Ongoing; Deal expected to close by the end of 2025
- Where
- Europe; Specifically Netherlands, UK, France
- Why
- To expand European market presence; prompted by US protectionist policies
United States
Indian Pharma
Trade Policy
United States
Increasing tariffs and protectionist policies on imported branded pharmaceutical products.
Indian Pharma
Focusing on European markets as a response to US protectionism.
- Acquisition Target
- VISUfarma BV
- Acquiring Company
- Lupin (via Nanomi BV)
- Purchase Price
- €190 million
- VISUfarma Products
- Ophthalmology (eye care) products
- Closing Date (Expected)
- End of 2025